obtaining and negotiatiing a position in industry/biotech

9
Obtaining and Negotiatiing a Position in Industry/Biotech Roy G. Smith Ph.D. Director, Huffington Center on Aging Professor, Department of Molecular and Cellular Biology (N704, [email protected])

Upload: holmes-soto

Post on 30-Dec-2015

15 views

Category:

Documents


1 download

DESCRIPTION

Obtaining and Negotiatiing a Position in Industry/Biotech. Roy G. Smith Ph.D. Director, Huffington Center on Aging Professor, Department of Molecular and Cellular Biology (N704, [email protected]). Background. Why pharmaceutical or biotech rather than academic career?. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Obtaining and Negotiatiing a Position in Industry/Biotech

Obtaining and Negotiatiing a Position in Industry/Biotech

Roy G. Smith Ph.D.Director, Huffington Center on Aging

Professor, Department of Molecular and Cellular Biology

(N704, [email protected])

Page 2: Obtaining and Negotiatiing a Position in Industry/Biotech

Background

• Why pharmaceutical or biotech rather than academic career?

Page 3: Obtaining and Negotiatiing a Position in Industry/Biotech

Requirements for Successful Career in Pharma/Biotech

• Passion to develop a new drug• Anticipate a tougher work ethic than academia• Interpersonal skills• Communication skills• Team building skills• Attention to detail – greater rigor necessary than

in academia• Fearless approach to disproving your hypothesis• Flexibility• Strong desire to learn the process from drug

discovery to FDA approval

Page 4: Obtaining and Negotiatiing a Position in Industry/Biotech

Discovery to New Drug Application (NDA)

TargetID

Target Valida-

tion

Lead Discovery

Drug Dev

Pre-Clinical

Clinical NDA

Safety Assessment

Phase I, II, IIIPharma. Process R&D

Basic Research Scientist, Chemists, Patent status, Pharmacologists, Formulation and Process Chemistry

Page 5: Obtaining and Negotiatiing a Position in Industry/Biotech

Research toIdentify New Drug Candidates• What is the market for your drug?• Selectivity• Potency• Pharmacokinetics• In vivo efficacy• Toxicity• Metabolism• Promiscuity screen

Page 6: Obtaining and Negotiatiing a Position in Industry/Biotech

GLP Safety Assessment• Toxicity in rats and dogs 3, 6, 12 month• P450 profile activator/inhibitor• Metabolite profile: comparison rat, dog, human (radiolabeled drug)• Organ distribution of drug• Cardiovascular toxicity• CNS toxicity• Reproductive toxicology

Preclinical Development

Page 7: Obtaining and Negotiatiing a Position in Industry/Biotech

Clinical Development

• Initiate and complete Preclinical Safety

•File IND and Initiate Phase I (healthy volunteers)

• Initiate Phase II (patients – dose selection)

•Phase III, Manufacturing and Marketing

• File NDA await FDA approval

Page 8: Obtaining and Negotiatiing a Position in Industry/Biotech

Estimated Drug Development Timelines

Q2‘02

Q1‘02

Q4‘03

Q3‘02

Q1‘03

Q2‘03

Q3‘03

Mfg

Q4‘02

Tox Studies

Phase I

Phase II

Additional Tox StudiesLead

Backup

Mfg

Tox Studies

Page 9: Obtaining and Negotiatiing a Position in Industry/Biotech

Tips for Negotiating

• Make it clear you have always wanted to develop a drug and that you know the process

• Indicate you are aware, what is important before beginning a new project is the potential market should you be successful

• If you express an idea for a drug/target show you are aware of competitive products – what is your advantage?

• Pick a target for a drug that meets and unmet medical need